Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesCoronaVac 및 ChAdox1 nCov-19(AZD1222) 백신으로 이종 프라임-부스트 백신 접종 후 면역원성 및 반응성Article Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] 95% CI 95% confidence interval Administered age age and sex antibody assigned AZD1222 binding domain booster dose Care ChAdOx1 nCoV-19 Cohort cohorts Combination Concentration control group CoronaVac COVID-19 COVID-19 pandemic effective elicited enrolled finding geometric mean ratio GMR Health Heterologous heterologous prime-boost homologous immune response immunogenicity indicated mass participant primary endpoint prime-boost interval RBD reactogenicity robust Safe the median vaccination Vaccine vaccine administration vaccine combination. while [DOI] 10.1080/21645515.2022.2052525 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
The Potential Role of an Adjunctive Real-Time Locating System in Preventing Secondary Transmission of SARS-CoV-2 in a Hospital Environment: Retrospective Case-Control StudyArticle Published on 2022-10-182022-11-16 Journal: Journal of Medical Internet Research [Category] COVID19(2023년), SARS, 치료기술, [키워드] 95% CI adjusted odds ratio Analysis approach case-control study conducted Contact Contact tracing COVID-19 COVID-19 patients diagnosed hospital In-hospital infection control limitation multivariable logistic regression performed positive Potential Preventing primary endpoint real-time locating system reduce retrospective role SARS-CoV-2 secondary secondary transmission secondary transmission. South Korea System university hospital Validity [DOI] 10.2196/41395 PMC 바로가기
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus [DOI] 10.1186/s13063-022-06791-y PMC 바로가기
Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal AntibodiesArticle Published on 2022-10-042022-11-15 Journal: Transplant International [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Administered Charlson Comorbidity Index complications COVID-19 COVID-19-related symptom death Diagnosis dose early administration early treatment Epidemiology Hospitalization incidence increased risk Infection kidney Kidney transplantation mAb mAbs monoclonal monoclonal antibodies monoclonal antibody Multivariate analysis Omicron variant onset of symptoms outcome Patient primary endpoint Primary outcome recipient role SARS-CoV-2 SARS-COV-2 infection significant decrease study period the SARS-CoV-2 Transplant vaccination [DOI] 10.3389/ti.2022.10721 PMC 바로가기
Increased respiratory dead space could associate with coagulation activation and poor outcomes in COVID-19 ARDSResearch article Published on 2022-10-012022-10-05 Journal: Journal of critical care [Category] 바이오마커, [키워드] Activation APACHE II ARDS Coagulation correlated COVID-19 COVID-19 patients Critically ill D-dimer D-dimer level determine discharge discharged enrolled help identify Increased Invasive mechanical ventilation less likelihood material measurement mechanical ventilation outcome outcomes P/F ratio Patient patients with COVID-19 performed Pneumonia primary endpoint Respiratory dead space Respiratory system Result static compliance subgroup of patient supported volumetric Volumetric capnography [DOI] 10.1016/j.jcrc.2022.154095 [Article Type] Research article
COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patientsShort communication Published on 2022-10-012022-10-30 Journal: Contemporary Clinical Trials Communications [Category] COVID-19, 임상, 치료법, [키워드] AE/SAE Analysis Angiotensin converting enzyme inhibitor (ACEi) Angiotensin II receptor Blocker (ARB) Arm baseline controls COVID-19 COVID-19 patients double-blinded Efficacy and safety Enrollment Final hospitalized COVID-19 patient hospitalized COVID-19 patients Hydroxychloroquine IMPROVE Lopinavir-ritonavir losartan Mortality MOST objective outcome pandemic parameter Patient Placebo placebo-controlled platform primary endpoint Randomized randomized clinical trial Randomized clinical trial (RCT) RCT Result SARS-CoV-2 score slow standard care the mean Treatment [DOI] 10.1016/j.conctc.2022.100968 [Article Type] Short communication
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infectionArticle Published on 2022-09-302022-11-15 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제, [키워드] 95% CI adverse event antibody Antiviral effect ARMS clinical trial clinical trials control arm COVID-19 infection COVID-19 symptom criteria enrolled evaluated experimental arm Frequency had no healthcare worker high risk in vitro incidence rate Infection infection with SARS-CoV-2 nitazoxanide no significant difference participant PCR testing Poisson regression model positive SARS-CoV-2 PCR primary endpoint randomization Randomized randomized trial risk safety analysis SARS-CoV-2 SARS-COV-2 infection serology shown sofosbuvir/daclatasvir South Africa Symptoms the primary endpoint Treatment Trial was selected was used [DOI] 10.1093/jac/dkac266 PMC 바로가기